Comparison of Topical Pranoprofen 0.1% and Bromfenac 0.1% for Acute Central Serous Chorioretinopathy
10.21561/jor.2024.9.2.112
- Author:
Eun Jin KANG
1
;
Yoon Hyung KWON
Author Information
1. Department of Ophthalmology, Dong-A University College of Medicine, Busan, Korea
- Publication Type:ORIGINAL ARTICLE
- From:
Journal of Retina
2024;9(2):112-118
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:To compare the efficacy of two kinds of topical nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute central serous chorioretinopathy (CSC).
Methods:A retrospective review was conducted on acute CSC patients that had been treated with topical NSAIDs and were followed for up to 3 months. In these patients, 101 eyes were treated with topical pranoprofen 0.1%, and 84 eyes were treated with topical bromfenac 0.1%. Baseline and follow-up values for best corrected visual acuity (BCVA), subfoveal choroidal thickness (SCT), and subretinal fluid (SRF) maximum height were examined and compared between groups.
Results:In both groups, mean BCVA, SCT, and SRF maximum height significantly improved throughout the follow-up period. Changes in the mean BCVA in the pranoprofen and bromfenac groups were respectively 0.05 logMAR and 0.05 logMAR at 1 month and 0.09 logMAR and 0.08 logMAR at 3 months, showing no statistical significance (p = 0.998, p = 0.540). Changes in SRF maximum height in the pranoprofen and bromfenac groups were 86.74 ± 104.48 µm and 104.81 ± 107.08 µm at 1 month and 138.66 ± 133.11 µm and 163.54 ± 136.24 µm at 3 months, respectively, showing no significant difference between the two groups (p =0.248 at 1 month, p = 0.212 at 3 months). Finally, SCT reductions in the two groups were 13.35 ± 16.36 µm and 24.26 ± 20.54 µm at 1 month and 16.15 ± 17.66 µm and 29.18 ± 29.49 µm at 3 months, showing a significant difference (independent t test, p = 0.000, p = 0.001). No serious adverse effects were reported.
Conclusions:Both topical bromfenac and pranoprofen are effective for structure and functional recovery in acute CSC. Bromfenac is statistically superior to pranoprofen in reducing the SCT of patients with CSC, which may reflect disease activity and the possibility of recurrence.
